Loading clinical trials...

Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER) | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNPhase 2NCT05640778

Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)

Evaluate the efficacy and safety of Dalpiciclib combined with aromatase inhibitors as a neoadjuvant therapy in Luminal B/HER2-negative breast cancer.

Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Yunxiang Zhou

CONTACT

+8615868131018 yxzhou@zju.edu.cn

Trial snapshot

StatusUNKNOWN

PhasePHASE2

Enrollment30

Start dateOct 2022

Last updatedJan 31, 2024

Condition

Luminal B/HER2-negative Breast Cancer

Locations shown

2nd Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 31, 2024Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions